Secondary stroke prevention

Decorative element

One in four stroke survivors will experience another stroke within five years.1

Cryptogenic, large-vessel, and small-vessel stroke patients can benefit from insertable cardiac monitoring (ICM) for atrial fibrillation (AF) detection, which helps inform secondary stroke prevention strategies.

Up to 30% of cryptogenic stroke patients and 21.7% of large- and small-vessel stroke patients have undetected paroxysmal AF at three years post-stroke.2,3



The link between AF and stroke

Watch clinician experts explain the data they capture using the LINQ II™ ICM, and how they use that data to make clinical treatment decisions for their AF patients.



Patient outcomes

Cryptogenic stroke/TIA patients who underwent prolonged cardiac monitoring show a 55% decreased risk of recurrent stroke.4

Decorative element

Additionally, compared to external monitors, ICM use in cryptogenic stroke patients was associated with5:

  • Faster time to AF diagnosis
  • Faster time to oral anticoagulation initiation
  • Reduced readmissions
  • Reduced rate of mortality


Why monitor longer?

When it comes to detecting AF in stroke patients, short-term monitoring is not enough. In fact, neurology and cardiology guidelines recommend long-term cardiac monitoring with ICMs for AF detection in cryptogenic stroke patients.6–9


Randomized trials have shown that AF is diagnosed in stroke patients well beyond 30 days.


CRYSTAL-AF2

  • 30% of cryptogenic stroke patients have AF detected up to three years post-stroke.
  • 84 days median time to AF detection in cryptogenic stroke patients at 12 months.
  • 88% of cryptogenic stroke patients who had AF would have been missed if only monitored for 30 days.

STROKE AF3

  • 21.7% of large- and small-vessel stroke patients have AF detected up to three years post-stroke.
  • 99 days median time to AF detection in large- and small-vessel stroke patients at 12 months.
  • 87% of large- and small-vessel stroke patients with AF would have been missed if only monitored for 30 days.

PER DIEM10

  • 15.3% AF detected with Medtronic ICM versus 4.7% with 30-day external loop recorder.
  • 70% of patients with AF were detected beyond 30 days.
  • All study patients with a “definite AF/high probability” diagnosis were started on an oral anticoagulant.



Why ICMs for secondary stroke prevention?

Watch as experts discuss the role of ICMs for secondary stroke prevention.




LINQ II™ and Reveal LINQ™ insertable cardiac monitors shown horizontally

Discover Medtronic ICMs.

Accuracy matters. When finding and treating AF in a stroke patient could mean preventing a recurrent stroke, you need a cardiac monitor you can rely on. Medtronic ICMs are the most accurate ICMs on the market,11–23 and are proven three times more effective for AF detection post-stroke than 30-day external monitors.10

Studies have also demonstrated that Medtronic ICMs are cost-effective for the prevention of secondary stroke through AF detection and subsequent medical management in a U.S. cryptogenic stroke population. In fact, immediate Medtronic ICM placement post-stroke was found to be cost-effective versus the standard of care, and cost-saving versus using an external monitor first.24 There is also a 50.2% estimated decrease in patient out-of-pocket costs with an ICM compared to using a 30-day monitor first.25



On-demand education

Watch webinars on secondary stroke prevention and the role of insertable cardiac monitoring.

Establish a stroke pathway.

Get information about how to get started with creating a stroke pathway.

AHA/ASA Cryptogenic Stroke Initiative

Access educational resources for healthcare professionals and patients.


Related products